CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Sevilla, Spain and 145 other locations
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...
Phase 2
Sevilla, Spain and 15 other locations
after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...
Phase 2
Sevilla, Spain and 9 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Sevilla, Spain and 126 other locations
(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...
Phase 3
Sevilla, Spain and 129 other locations
dexamethasone) in newly diagnosed (ND) transplant eligible multiple myeloma (MM) patients.Eligible patients will be included in the...
Phase 2
Sevilla, Andalucia, Spain and 17 other locations
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose o...
Phase 1
Sevilla, Spain and 48 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Sevilla, Spain and 180 other locations
antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...
Phase 3
Sevilla, Spain and 270 other locations
Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...
Phase 3
Sevilla, Spain and 135 other locations
Clinical trials
Research sites
Resources
Legal